Skip to main content

Will Mylan Crush Teva’s Generic Dreams?

Bad news may be baked into shares of drug makers Mylan and Teva even as a new generic poses a pricing challenge.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.